Telix will acquire ITM for $1.65 billion upfront, adding radioisotope manufacturing capabilities and ITM-11 to its radiopharmaceutical pipeline.
Written By: Siddhi Bhadekar, M. Pharm (QA)
Reviewed By: Pharmacally Editorial Team
Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich SE for $1.65 billion in upfront consideration, with up to $700 million in additional milestone payments linked to ITM-11. If all milestones are achieved, total consideration could reach $2.35 billion, bringing together Telix’s radiopharmaceutical portfolio with ITM’s commercial-scale radioisotope manufacturing and global distribution capabilities.
Telix Expands Across the Radiopharmaceutical Value Chain
The proposed transaction would create a more vertically integrated radiopharmaceutical company spanning therapeutic development, radioisotope production, manufacturing and global distribution.
Founded in 2004, ITM operates a commercial-scale radioisotope manufacturing and distribution network covering more than 65 countries. Its capabilities include production of lutetium-177 (^177Lu), actinium-225 (^225Ac) and terbium-161 (^161Tb), with ^177Lu representing a major component of its commercial business.
ITM generated $273 million in revenue in 2025, with revenue growing at a reported compound annual growth rate of 40% between 2021 and 2025. Its isotope manufacturing business is profitable and generates cash flow, which could strengthen Telix’s supply chain for radioisotopes required across its therapeutic pipeline.
ITM-11 Adds a Late-Stage Therapeutic Program
A key component of the transaction is ITM-11 (^177Lu-edotreotide), an SSTR-targeted radiopharmaceutical being developed for gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
ITM-11 has completed the Phase 3 COMPETE trial (NCT03049189). ITM has also fully enrolled the Phase 3 COMPOSE study (NCT04919226), which is evaluating the therapy in an expanded indication, with an interim analysis expected in the first half of 2027.
If approved, ITM-11 could provide Telix with an entry into an established therapeutic market for targeted radionuclide therapy and expand its presence in neuroendocrine tumors.
Transaction Structure and Financial Terms
Telix will acquire 100% of ITM for $1.65 billion in upfront consideration on a cash-free, debt-free basis.
Approximately $1.25 billion will be paid to ITM shareholders through 105.8 million Telix shares priced at $11.84 per share, based on Telix’s 30-day trailing volume-weighted average price at signing. Telix will also assume approximately $302 million in net debt, while $96 million covers management equity rollover and transaction expenses, subject to closing adjustments.
The deal includes up to $700 million in additional contingent consideration linked to ITM-11. Up to $250 million will be tied to U.S. Food and Drug Administration approvals across three indications: G1-G2 GEP-NETs, G2-G3 GEP-NETs and lung NETs. A further $450 million will depend on ITM-11 global sales exceeding $150 million in fiscal 2030.
All milestone payments may be made in cash or Telix shares at the company’s election.
Combined Business Targets More Than $1.3 Billion in 2026 Revenue
Telix expects the combined organization to generate unaudited pro forma 2026 revenue and income exceeding $1.3 billion, based on management estimates. The company expects ITM’s manufacturing operations, cost savings, synergies and pipeline optimization to support a positive EBITDA contribution from 2027 onward.
Telix CEO Dr. Christian Behrenbruch said the combination would strengthen isotope supply and add two late-stage Phase 3 programs to the company’s therapeutic pipeline. ITM-11 has completed the Phase 3 COMPETE trial, while the Phase 3 COMPOSE study is fully enrolled and remains under evaluation, with an interim analysis expected in the first half of 2027.
ITM CEO Dr. Andrew Cavey said combining the companies would bring together complementary capabilities across radioisotope production, radiopharmaceutical development, manufacturing and commercial operations.
Closing Expected by Year-End 2026
The transaction has been approved by Telix’s Board of Directors and, at signing, by shareholders holding more than 90% of ITM’s shares. Completion remains subject to Telix shareholder approval, regulatory clearances and other customary closing conditions.
If completed, Telix shareholders are expected to own approximately 76.3% of the combined company, while ITM shareholders would hold approximately 23.7%. Telix expects the transaction to close by the end of fiscal 2026.
The combination would give Telix greater control over a critical part of the radiopharmaceutical supply chain while adding ITM-11 as a late-stage therapeutic asset. The next major development milestones include the transaction’s regulatory and shareholder approvals and the expected 2027 interim analysis from the COMPOSE Phase 3 study.
Reference
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse, Telix, 21 September 2026
About the Writer
Siddhi Rajendra Bhadekar (Linkedin) is an M.Pharm professional with expertise in medical and scientific writing, literature review, publication writing, and evidence synthesis, supported by four peer-reviewed publications.
She brings working knowledge of ICH-GCP, MedDRA, pharmacovigilance, ADR/AE reporting, clinical data management, and regulatory documentation.
With experience across pharmaceutical R&D, Quality Control, and Quality Assurance, she combines scientific research skills with strong attention to accuracy and detail.
Her background in manuscript development, publication planning, and scientific communication enables her to translate complex healthcare information into clear, reliable content.